vs
Sprinklr, Inc.（CXM）与PHIBRO ANIMAL HEALTH CORP（PAHC）财务数据对比。点击上方公司名可切换其他公司
PHIBRO ANIMAL HEALTH CORP的季度营收约是Sprinklr, Inc.的1.7倍（$373.9M vs $219.1M），PHIBRO ANIMAL HEALTH CORP净利率更高（7.3% vs 1.3%，领先6.0%），PHIBRO ANIMAL HEALTH CORP同比增速更快（20.9% vs 9.2%），Sprinklr, Inc.自由现金流更多（$19.8M vs $8.3M），过去两年PHIBRO ANIMAL HEALTH CORP的营收复合增速更高（19.2% vs 6.2%）
Sprinklr是美国的一家SaaS企业，专注于客户体验管理（CXM）平台研发。其同名产品整合了社媒营销、社交广告、内容管理、团队协作、员工倡导、客户服务、社媒调研与监测等多类应用模块，为企业提供全链路的客户体验管理解决方案。
菲宝罗动物保健公司是一家美国动物健康与矿物质营养企业，主营产品涵盖抗菌药、抗球虫药、驱虫药，以及畜禽营养补充剂、疫苗等。公司下设矿物质营养、功能材料、动物健康三大业务板块，收入主要来源于上述板块，业务遍及美国、拉美、加拿大、欧洲、中东、非洲及亚太地区。
CXM vs PAHC — 直观对比
营收规模更大
PAHC
是对方的1.7倍
$219.1M
营收增速更快
PAHC
高出11.7%
9.2%
净利率更高
PAHC
高出6.0%
1.3%
自由现金流更多
CXM
多$11.5M
$8.3M
两年增速更快
PAHC
近两年复合增速
6.2%
损益表 — Q3 FY2026 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $219.1M | $373.9M |
| 净利润 | $2.9M | $27.5M |
| 毛利率 | 66.4% | 35.5% |
| 营业利润率 | 5.3% | 13.5% |
| 净利率 | 1.3% | 7.3% |
| 营收同比 | 9.2% | 20.9% |
| 净利润同比 | -72.2% | 762.1% |
| 每股收益（稀释后） | $0.01 | $0.67 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CXMPAHC
| Q4 25 | $219.1M | $373.9M | ||
| Q3 25 | $212.0M | $363.9M | ||
| Q2 25 | $205.5M | $378.7M | ||
| Q1 25 | $202.5M | $347.8M | ||
| Q4 24 | $200.7M | $309.3M | ||
| Q3 24 | $197.2M | $260.4M | ||
| Q2 24 | $196.0M | $273.2M | ||
| Q1 24 | $194.2M | $263.2M |
净利润CXMPAHC
| Q4 25 | $2.9M | $27.5M | ||
| Q3 25 | $12.6M | $26.5M | ||
| Q2 25 | $-1.6M | $17.2M | ||
| Q1 25 | $98.7M | $20.9M | ||
| Q4 24 | $10.5M | $3.2M | ||
| Q3 24 | $1.8M | $7.0M | ||
| Q2 24 | $10.6M | $752.0K | ||
| Q1 24 | $21.1M | $8.4M |
毛利率CXMPAHC
| Q4 25 | 66.4% | 35.5% | ||
| Q3 25 | 68.2% | 32.9% | ||
| Q2 25 | 69.5% | 29.0% | ||
| Q1 25 | 71.0% | 30.1% | ||
| Q4 24 | 71.2% | 32.9% | ||
| Q3 24 | 72.6% | 32.1% | ||
| Q2 24 | 73.9% | 31.9% | ||
| Q1 24 | 75.5% | 30.2% |
营业利润率CXMPAHC
| Q4 25 | 5.3% | 13.5% | ||
| Q3 25 | 7.7% | 14.1% | ||
| Q2 25 | -0.9% | 8.9% | ||
| Q1 25 | 5.2% | 9.6% | ||
| Q4 24 | 3.9% | 8.3% | ||
| Q3 24 | -0.0% | 6.8% | ||
| Q2 24 | 2.9% | 6.7% | ||
| Q1 24 | 9.5% | 7.6% |
净利率CXMPAHC
| Q4 25 | 1.3% | 7.3% | ||
| Q3 25 | 5.9% | 7.3% | ||
| Q2 25 | -0.8% | 4.5% | ||
| Q1 25 | 48.7% | 6.0% | ||
| Q4 24 | 5.2% | 1.0% | ||
| Q3 24 | 0.9% | 2.7% | ||
| Q2 24 | 5.4% | 0.3% | ||
| Q1 24 | 10.9% | 3.2% |
每股收益（稀释后）CXMPAHC
| Q4 25 | $0.01 | $0.67 | ||
| Q3 25 | $0.05 | $0.65 | ||
| Q2 25 | $-0.01 | $0.43 | ||
| Q1 25 | $0.35 | $0.51 | ||
| Q4 24 | $0.04 | $0.08 | ||
| Q3 24 | $0.01 | $0.17 | ||
| Q2 24 | $0.04 | $0.02 | ||
| Q1 24 | $0.07 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $189.6M | $74.5M |
| 总债务越低越好 | — | $624.2M |
| 股东权益账面价值 | $558.1M | $332.4M |
| 总资产 | $1.1B | $1.4B |
| 负债/权益比越低杠杆越低 | — | 1.88× |
8季度趋势，按日历期对齐
现金及短期投资CXMPAHC
| Q4 25 | $189.6M | $74.5M | ||
| Q3 25 | $125.4M | $85.3M | ||
| Q2 25 | $126.4M | $77.0M | ||
| Q1 25 | $145.3M | $70.4M | ||
| Q4 24 | $93.2M | $67.1M | ||
| Q3 24 | $119.1M | $89.8M | ||
| Q2 24 | $126.8M | $114.6M | ||
| Q1 24 | $164.0M | $98.7M |
总债务CXMPAHC
| Q4 25 | — | $624.2M | ||
| Q3 25 | — | $628.0M | ||
| Q2 25 | — | $631.7M | ||
| Q1 25 | — | $635.4M | ||
| Q4 24 | — | $639.1M | ||
| Q3 24 | — | $295.2M | ||
| Q2 24 | — | $312.1M | ||
| Q1 24 | — | — |
股东权益CXMPAHC
| Q4 25 | $558.1M | $332.4M | ||
| Q3 25 | $543.4M | $311.7M | ||
| Q2 25 | $639.8M | $285.7M | ||
| Q1 25 | $612.1M | $266.0M | ||
| Q4 24 | $497.0M | $246.8M | ||
| Q3 24 | $469.0M | $258.5M | ||
| Q2 24 | $610.9M | $256.6M | ||
| Q1 24 | $679.7M | $270.1M |
总资产CXMPAHC
| Q4 25 | $1.1B | $1.4B | ||
| Q3 25 | $1.1B | $1.4B | ||
| Q2 25 | $1.2B | $1.4B | ||
| Q1 25 | $1.2B | $1.3B | ||
| Q4 24 | $970.3M | $1.3B | ||
| Q3 24 | $983.8M | $966.3M | ||
| Q2 24 | $1.1B | $982.2M | ||
| Q1 24 | $1.2B | $979.0M |
负债/权益比CXMPAHC
| Q4 25 | — | 1.88× | ||
| Q3 25 | — | 2.01× | ||
| Q2 25 | — | 2.21× | ||
| Q1 25 | — | 2.39× | ||
| Q4 24 | — | 2.59× | ||
| Q3 24 | — | 1.14× | ||
| Q2 24 | — | 1.22× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $20.0M | $19.4M |
| 自由现金流经营现金流 - 资本支出 | $19.8M | $8.3M |
| 自由现金流率自由现金流/营收 | 9.0% | 2.2% |
| 资本支出强度资本支出/营收 | 0.1% | 3.0% |
| 现金转化率经营现金流/净利润 | 6.87× | 0.70× |
| 过去12个月自由现金流最近4个季度 | $142.3M | $47.3M |
8季度趋势，按日历期对齐
经营现金流CXMPAHC
| Q4 25 | $20.0M | $19.4M | ||
| Q3 25 | $34.8M | $9.3M | ||
| Q2 25 | $83.8M | $21.3M | ||
| Q1 25 | $5.4M | $43.2M | ||
| Q4 24 | $9.2M | $3.1M | ||
| Q3 24 | $21.3M | $12.6M | ||
| Q2 24 | $41.7M | $28.4M | ||
| Q1 24 | $17.3M | $11.4M |
自由现金流CXMPAHC
| Q4 25 | $19.8M | $8.3M | ||
| Q3 25 | $34.4M | $-4.5M | ||
| Q2 25 | $83.5M | $8.1M | ||
| Q1 25 | $4.6M | $35.4M | ||
| Q4 24 | $8.2M | $-4.7M | ||
| Q3 24 | $19.8M | $3.0M | ||
| Q2 24 | $39.2M | $15.4M | ||
| Q1 24 | $15.2M | $1.7M |
自由现金流率CXMPAHC
| Q4 25 | 9.0% | 2.2% | ||
| Q3 25 | 16.2% | -1.2% | ||
| Q2 25 | 40.6% | 2.1% | ||
| Q1 25 | 2.3% | 10.2% | ||
| Q4 24 | 4.1% | -1.5% | ||
| Q3 24 | 10.1% | 1.2% | ||
| Q2 24 | 20.0% | 5.6% | ||
| Q1 24 | 7.9% | 0.6% |
资本支出强度CXMPAHC
| Q4 25 | 0.1% | 3.0% | ||
| Q3 25 | 0.2% | 3.8% | ||
| Q2 25 | 0.1% | 3.5% | ||
| Q1 25 | 0.4% | 2.2% | ||
| Q4 24 | 0.5% | 2.5% | ||
| Q3 24 | 0.8% | 3.7% | ||
| Q2 24 | 1.3% | 4.8% | ||
| Q1 24 | 1.1% | 3.7% |
现金转化率CXMPAHC
| Q4 25 | 6.87× | 0.70× | ||
| Q3 25 | 2.76× | 0.35× | ||
| Q2 25 | — | 1.24× | ||
| Q1 25 | 0.05× | 2.07× | ||
| Q4 24 | 0.88× | 0.97× | ||
| Q3 24 | 11.58× | 1.81× | ||
| Q2 24 | 3.92× | 37.80× | ||
| Q1 24 | 0.82× | 1.36× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CXM
| License And Service | $190.3M | 87% |
| Professional Services | $28.8M | 13% |
PAHC
| Medicated Feed Additives And Others | $202.1M | 54% |
| Mineral Nutrition | $68.9M | 18% |
| Nutritional Specialties | $50.2M | 13% |
| Vaccines | $37.6M | 10% |
| Performance Products | $15.0M | 4% |
